Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Plaque Psoriasis Clinical Trial

Official title:

A Phase IV, Randomized, Double-blind, Parallel-group, Multiple-dose, Active Comparator, Multicenter Clinical Study to Evaluate the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05510063
• Other study ID #: SB5-4001
• Status: Completed
• Phase: Phase 4
• Start date: August 4, 2022
• Est. completion date: May 4, 2023

Study information

• Verified date: May 2023
• Source: Samsung Bioepis Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase IV, randomized, double-blind, parallel-group, multiple-dose, active comparator, multicenter clinical study to evaluate the pharmacokinetics, efficacy, safety, and immunogenicity of SB5 versus Humira in subjects with moderate to severe chronic plaque psoriasis.

Description:

The primary objective of this study is to assess the pharmacokinetic similarity in subjects with moderate to severe plaque psoriasis who switch between Humira and SB5 to those receiving Humira continuously.

All entered subjects will be treated with Humira during a lead-in period of 13 weeks. At Week 13, subjects who achieved at least a 50% reduction in Psoriasis Area and Severity Index (PASI50) response will be randomized in a 1:1 ratio to either be switched between Humira and SB5 or continue on Humira.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 371
• Est. completion date: May 4, 2023
• Est. primary completion date: April 4, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Have no history of Adalimumab and cell-depleting biologics

• Have no history of any other biologics use within 6 months prior to Week 0

• Have plaque psoriasis diagnosed at least 6 months, with or without psoriatic arthritis

• Have plaque psoriasis with the involvement and severity of total affected BSA = 10%, PASI score of = 12 and PGA score of = 3 (moderate)

• Considered to be a candidate for phototherapy or systemic therapy for psoriasis

• Adequate hematological, renal, and hepatic function by central lab

• Non-childbearing potential female, or childbearing potential female subjects or male subjects with their partners who agree to use at least two forms of appropriate contraception method from Screening until 5 months after the last dose of IP

Exclusion Criteria:

• Have nonplaque forms of psoriasis, including erythrodermic, pustular, guttate, or drug-induced psoriasis

• Have other skin disease than psoriasis that requires topical, phototherapy or systemic therapy

• Known allergic reactions or hypersensitivity to adalimumab or to any ingredients of SB5 or Humira

• Have received phototherapy or conventional systemic therapy within 4 weeks prior to Week 0

• Have received topical therapy for psoriasis within 2 weeks prior to Week 0, however class 6/7 corticosteroids are allowed on face and groin

• Women who are pregnant or nursing at Screening, or men and women planning pregnancy during the study period and until 5 months after the last dose of IP

• Have received a live or live attenuated viral vaccine or a live bacterial vaccine within 8 weeks prior to Week 0. Non-live COVID-19 vaccines are allowed

• Have active or latent tuberculosis

• History of ongoing infection or a positive test of HBV, HCV, or HIV infection

• History of sepsis, chronic or recurrent infection

• History of lymphoproliferative disease or leukaemia

• History of malignancy within the last 5 years

Related Conditions & MeSH terms

• Plaque Psoriasis
• Psoriasis

Intervention

Drug:
• Humira (Adalimumab)
Subcutaneous (SC) injection
• SB5 (Adalimumab Biosimilar)
Subcutaneous (SC) injection

Locations

Country	Name	City	State
Bulgaria	SB Investigative Site	Dupnitsa
Bulgaria	SB Investigative Site	Pleven
Bulgaria	SB Investigative Site	Sofia
Czechia	SB Investigative Site	Ostrava
Czechia	SB Investigative Site	Pardubice
Czechia	SB Investigative Site	Praha
Czechia	SB Investigative Site	Praha 10
Lithuania	SB Investigative Site	Kaunas
Lithuania	SB Investigative Site	Vilnius
Poland	SB Investigative Site	Bialystok
Poland	SB Investigative Site	Bydgoszcz
Poland	SB Investigative Site	Gdansk
Poland	SB Investigative Site	Gdynia
Poland	SB Investigative Site	Kraków
Poland	SB Investigative Site	Lódz
Poland	SB Investigative Site	Lublin
Poland	SB Investigative Site	Nowa Sól
Poland	SB Investigative Site	Olsztyn
Poland	SB Investigative Site	Osielsko
Poland	SB Investigative Site	Poznan
Poland	SB Investigative Site	Siedlce
Poland	SB Investigative Site	Swidnik
Poland	SB Investigative Site	Szczecin
Poland	SB Investigative Site	Warszawa

Sponsors (2)

Lead Sponsor	Collaborator
Samsung Bioepis Co., Ltd.	Organon and Co

Countries where clinical trial is conducted

Bulgaria,  Czechia,  Lithuania,  Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area under the concentration-time curve over the dosing interval (AUCtau)		Week 23 to Week 25
Primary	Maximum serum concentration during the dosing interval (Cmax)		Week 23 to Week 25